Has Dhaval Parekh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $148,209 in general payments to Dhaval Parekh, MD across 611 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dhaval Parekh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dhaval Parekh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dhaval Parekh, MD

Interventional Cardiology · Houston, TXNPI 1942336078

Payments from drug & device makers

$148,209in general payments, 2019–2025

Across 611 payments — averaging $242.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$85K
W. L. Gore & Associates, Inc.$29K
Medtronic$13K
Edwards Lifesciences$7K
Penumbra, Inc.$3K
Angiodynamics, Inc.$3K
plus $8K from 34 others

$315in research payments, 2019–2025

Across 2 payments — averaging $157.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abiomed$315

What the payments were for

Consulting fees$92,25067%
Travel & lodging$18,97514%
Food & beverage$26,26019%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	155	$84,998
W. L. Gore & Associates, Inc.	45	$29,469
Medtronic(2 entities)	111	$13,011
Edwards Lifesciences	112	$6,873
Penumbra, Inc.	14	$3,232
Angiodynamics, Inc.	16	$3,044
Boston Scientific	21	$1,618
Impulse Dynamics (USA) Inc.	16	$1,271
Abiomed	13	$1,140
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	20	$738
Shockwave Medical, Inc	3	$381
Johnson & Johnson	16	$286
Inari Medical, Inc.	3	$249
Biosense Webster, Inc.	2	$248
Endologix LLC	2	$212
Irhythm Technologies, Inc.	11	$153
Biotronik Inc.	6	$141
Novartis	6	$139
Actelion Pharmaceuticals US, Inc.	4	$112
Cagent Vascular Inc	1	$112
Cook Medical LLC	1	$100
Amgen	4	$78
Astellas Pharma US Inc	3	$67
Cardiva Medical, Inc.	2	$55
Portola Pharmaceuticals, LLC	2	$54
Philips North America LLC	2	$49
Contego Medical, Inc	1	$46
Scpharmaceuticals Inc.	3	$40
E.r. Squibb & Sons, L.L.C.	2	$37
Chiesi USA, Inc.	2	$37
Bayer	2	$34
AstraZeneca	2	$30
Kiniksa Pharmaceuticals International, PLC	1	$28
Cardinal Health 200 LLC	1	$28
Avinger Inc.	1	$23
Boehringer Ingelheim	1	$22
Teleflex LLC	1	$18
Supernus Pharmaceuticals, Inc.	1	$17
Ancora Heart, Inc.	1	$10
Bardy Diagnostics, Inc.	1	$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AMPLATZER Occluders$45,617
AMPLATZER TALISMAN$18,403
GORE CARDIOFORM Septal Occluder$16,354
AMPLATZER$11,103
HARMONY$6,578
AMPLATZER AMULET$4,313
Indigo System$3,166
Edwards SAPIEN 3 Transcatheter Heart Valve$2,364
GORE CARDIOFORM ASD Occluder$1,950
AlphaVac$1,705
AngioVac$1,239
OPTIMIZER$1,223
THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM$1,186
Melody$1,073
Mitra Clip system$1,068
MELODY TPV$824
COREVALVE EVOLUT R$768
CARDIOMEMS$505
SYMPLICITY G3$451
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$381

How this compares

$148,209 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas →

Medicare billing

Part B allowed, 2024

$60,238

Medicare patients

154

Services billed

426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	14	$12,945
Atorvastatin Calcium	25	$242
Carvedilol	15	$206
Pantoprazole Sodium	12	$182
Metoprolol Tartrate	18	$147
Metoprolol Succinate	15	$126
Amlodipine Besylate	16	$110
ClopidogrelClopidogrel Bisulfate	19	$54

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Houston

Neal KleimanHouston$4.8M
Juan GranadaHouston$4.3M
Abhijeet DhobleHouston$2.7M
John IsaacHouston$1.8M
Amir KashaniHouston$1.3M
Biswajit KarHouston$785K
Michele SartoriHouston$603K
Guilherme SilvaHouston$516K
Sachin KumarHouston$446K
Marwan JumeanHouston$427K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →